Last Updated: November 16, 2026

Expiring Drug Patents Cheat Sheet
We analyse the patents covering drugs in 134 countries and quickly give you the likely loss-of-exclusivity/generic entry date

➤ Get the Full List

San Marino: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027

The content of this page is licensed under a Creative Commons Attribution 4.0 International License. Creative Commons License

Preferred citation:
Friedman, Yali, "San Marino: These 4 Drugs Face Patent Expirations and Generic Entry From 2026 - 2027" DrugPatentWatch.com thinkBiotech, 2026 www.drugpatentwatch.com/p/expiring-drug-patents-generic-entry/.
Media collateral
These estimated drug patent expiration dates and generic entry opportunity dates are calculated from analysis of known patents covering drugs. Many factors can influence early or late generic entry. This information is provided as a rough estimate of generic entry potential and should not be used as an independent source. The methodology is described in this blog post.
When can ZYKADIA (ceritinib) generic drug versions launch in San Marino?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: San Marino Patent 201,000,108
Patent Title: Composti e composizioni come inibitori di proteinachinasi.

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can ZYKADIA (ceritinib) generic drug versions launch in San Marino?

Generic name: ceritinib
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: December 08, 2026
Generic Entry Controlled by: San Marino Patent P200900058

ZYKADIA is a drug marketed by Novartis. There are eight patents protecting this drug.

See drug price trends for ZYKADIA.

The generic ingredient in ZYKADIA is ceritinib. Additional details are available on the ceritinib profile page.

When can SIGNIFOR LAR (pasireotide pamoate) generic drug versions launch in San Marino?

Generic name: pasireotide pamoate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: May 24, 2027
Generic Entry Controlled by: San Marino Patent P200900099

SIGNIFOR LAR is a drug marketed by Recordati Rare. There are three patents protecting this drug.

See drug price trends for SIGNIFOR LAR.

The generic ingredient in SIGNIFOR LAR is pasireotide pamoate. Additional details are available on the pasireotide pamoate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in San Marino?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: San Marino Patent AP201000002
Patent Title: Sali dell'inibitore di chinasi janus (r)-3-(4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazoli-1-il)-3-ciclopentilpropanonitrile

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can JAKAFI (ruxolitinib phosphate) generic drug versions launch in San Marino?

Generic name: ruxolitinib phosphate
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 13, 2027
Generic Entry Controlled by: San Marino Patent P201000002
Patent Title: Sali dell'inibitore di chinasi janus (R)-3-(4-(7H-pirrolo[2,3-D]pirimidin-4-IL)-1H-pirazoli-1-IL)-3-ciclopentilpropanonitrile

JAKAFI is a drug marketed by Incyte Corp. There are nineteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering JAKAFI

See drug price trends for JAKAFI.

The generic ingredient in JAKAFI is ruxolitinib phosphate. Additional details are available on the ruxolitinib phosphate profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in San Marino?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: San Marino Patent AP201000003
Patent Title: Composizione, metodo e preparazione di acidi biliari sintetici

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

When can KYBELLA (deoxycholic acid) generic drug versions launch in San Marino?

Generic name: deoxycholic acid
DrugPatentWatch® Estimated Key Patent Expiration / Generic Entry Date: June 19, 2027
Generic Entry Controlled by: San Marino Patent P201000003
Patent Title: Composizione, metodo e preparazione di acidi biliari sintetici.

KYBELLA is a drug marketed by Abbvie. There are fourteen patents protecting this drug and one Paragraph IV challenge. There has been litigation on patents covering KYBELLA

The generic ingredient in KYBELLA is deoxycholic acid. Additional details are available on the deoxycholic acid profile page.

San Marino Branded and Generic Drug Market Assessment: Regulation, Market Access and Commercial Opportunities

Last updated: October 21, 2026

San Marino is a small, import-dependent pharmaceutical market integrated commercially and clinically with Italy. Its opportunity lies in specialized medicines, hospital products, generic substitution, pharmacy distribution and cross-border healthcare rather than domestic scale. Regulatory access is relatively manageable for products already authorized in Italy or the European Union, but San Marino is not an EU member and does not provide automatic EU market authorization. The main challenges are limited market volume, public procurement concentration, dependence on Italian supply chains, uncertain standalone market data and administrative requirements for local importation, reimbursement and pharmacovigilance.

What is the size and structure of San Marino’s pharmaceutical market?

San Marino has a population of approximately 34,000 to 35,000 people and a health system centered on the state-linked Istituto per la Sicurezza Sociale, or ISS. The country’s small population limits absolute pharmaceutical demand, while its high-income economy and proximity to Italy support demand for chronic-care, specialty and outpatient medicines (World Bank, 2024; U.S. Department of State, 2024).

San Marino does not publish a widely used, standalone pharmaceutical market dataset comparable to IQVIA country reports for larger European markets. Commercial analysis therefore depends on procurement records, pharmacy sales, import data, ISS reimbursement information, local distributors and Italian market benchmarks.

Market characteristic San Marino assessment
Population base Approximately 34,000-35,000 residents
Primary supply route Imports, principally through Italy and Italian-linked wholesalers
Health-system buyer ISS and affiliated public healthcare structures
Retail channel Community pharmacies and licensed distributors
Hospital channel Public-sector procurement and institutional purchasing
Domestic manufacturing No meaningful finished-dose pharmaceutical manufacturing base
Regulatory alignment Strong practical alignment with Italy and European standards, but no automatic EU authorization
Market scale Micro-market; commercial value depends on product price and clinical specialty
Main demand drivers Aging, chronic disease, outpatient maintenance therapy and specialty care
Main commercial constraint Low volume and concentrated purchasing

San Marino’s pharmaceutical demand is likely concentrated in cardiovascular, metabolic, respiratory, gastrointestinal, neurological, oncology and anti-infective products. High-cost specialty medicines can materially affect expenditure despite low patient numbers.

How does San Marino regulate medicines?

San Marino regulates medicines through its national health and pharmaceutical administration, with implementation involving the ISS and the country’s pharmaceutical office or competent health authorities. The practical framework is closely connected to Italian and European pharmaceutical standards because most medicines are sourced from Italy or other European markets.

A company seeking access generally needs to address five regulatory functions:

  1. Authorization or recognition of the medicinal product.
  2. Importation through an approved operator.
  3. Wholesale distribution and storage compliance.
  4. Pharmacovigilance and quality-defect reporting.
  5. Pricing, reimbursement and procurement access.

San Marino should not be treated as an EU member state. An EU marketing authorization does not, by itself, create an automatic right to sell a product in San Marino. A local recognition, notification, importation approval or national administrative step may still be required.

What regulatory documents are normally relevant?

For a product already authorized in Italy or the EU, the local submission package is likely to rely on existing European technical documentation, including:

  • Marketing authorization certificate.
  • Summary of Product Characteristics.
  • Package leaflet and labeling.
  • Good Manufacturing Practice documentation.
  • Good Distribution Practice documentation.
  • Certificate of Pharmaceutical Product, where requested.
  • Pharmacovigilance system information.
  • Stability and batch-release documentation.
  • Local representative or importer details.
  • Pricing and reimbursement information.

The precise filing route depends on the product type, source country, legal basis of the authorization and the requirements applied by San Marino’s health authorities.

What are the opportunities for branded drug companies?

Branded companies can access San Marino through products with established Italian or EU authorization, especially when the product has clinical differentiation, reimbursement support or limited generic competition.

Specialty and hospital medicines

The most commercially relevant opportunities are likely to involve:

  • Oncology medicines.
  • Orphan drugs.
  • Immunology and biologics.
  • Anticoagulants.
  • Diabetes and obesity therapies.
  • Neurology products.
  • Long-acting injectable medicines.
  • Hospital anti-infectives.
  • Rare-disease treatments.

In a micro-market, the number of eligible patients may be small, but the annual treatment cost per patient can be high. Market entry should therefore focus on reimbursement and procurement mechanics rather than broad promotional spending.

Branded generics and line extensions

Branded generics can compete where prescribers and pharmacies value supply reliability, Italian-language materials, established manufacturing quality or portfolio breadth. Reformulated products, fixed-dose combinations and modified-release medicines may have stronger commercial positioning than undifferentiated immediate-release products.

Digital and specialty-service models

Manufacturers can create value through:

  • Patient-support programs.
  • Cold-chain monitoring.
  • Hospital supply planning.
  • Pharmacist education.
  • Adherence services.
  • Electronic ordering and inventory management.
  • Regional supply agreements with Italian distributors.

These programs need to comply with local privacy, promotion and healthcare-professional rules.

What are the opportunities for generic drug companies?

San Marino is structurally favorable to generic penetration because it relies on imported medicines and has a small number of institutional and pharmacy buyers. The strongest opportunity is usually not a standalone San Marino launch. It is a regional launch using an Italian or EU commercial platform with San Marino added as a low-cost extension market.

High-potential generic categories

Generic companies should prioritize products with:

  • Established Italian or EU authorization.
  • Multiple approved suppliers.
  • Stable demand.
  • Low cold-chain dependence.
  • Simple storage requirements.
  • Limited shortage history.
  • Clear substitution potential.
  • Competitive ex-factory pricing.

Typical categories include antihypertensives, statins, proton-pump inhibitors, oral antidiabetics, antidepressants, respiratory medicines and common anti-infectives.

Biosimilars

Biosimilar opportunities exist in oncology, immunology, endocrinology and supportive care. The commercial case depends on whether San Marino recognizes or accepts the relevant EU or Italian authorization pathway and how ISS procurement evaluates interchangeability, tender price and clinical policy.

Biosimilars face several constraints:

  • Low patient volume.
  • Concentrated hospital purchasing.
  • Need for physician confidence.
  • Cold-chain requirements.
  • Dependence on tender timing.
  • Potential preference for incumbent biologics.
  • Need for pharmacovigilance and traceability.

A biosimilar supplier should treat San Marino as part of an Italy-centered tender and supply strategy rather than as an independent launch market.

What is the patent and exclusivity position in San Marino?

Patent protection can affect branded and generic entry, but regulatory exclusivity and commercial availability are more important than patent litigation in this market.

San Marino is associated with the European patent system, and European patent protection may be available through validation or other applicable national procedures. Patent owners must confirm the territorial effect of each European patent and whether San Marino is designated and properly validated. A European patent should not be assumed to have enforceable effect in San Marino without reviewing the relevant grant and validation records.

Exclusivity issue San Marino commercial effect
Product patent Can delay local generic entry if enforceable in San Marino
Process patent May restrict manufacturing or importation routes
Formulation patent Relevant for modified-release, injectable and combination products
Method-of-use patent Can affect a specific reimbursed indication
Regulatory data exclusivity Requires assessment under applicable national rules
SPC protection Must be checked separately; EU status does not automatically determine San Marino effect
Orphan exclusivity Depends on national recognition or reliance on foreign authorization
Patent litigation Likely less frequent than in Italy because of market size

There is no San Marino equivalent of the U.S. FDA Orange Book. Companies should not assume that a patent listed in the Italian or European regulatory system is automatically listed or enforceable in San Marino. Freedom-to-operate analysis should review:

  • European Patent Office records.
  • National validation status.
  • Patent ownership and assignments.
  • San Marino national registers.
  • Product authorization status.
  • Importer and distributor arrangements.
  • Applicable court jurisdiction.

When do branded products lose exclusivity in San Marino?

There is no single market-wide loss-of-exclusivity calendar. Entry depends on the expiry and enforceability of relevant patents, regulatory exclusivity, local authorization requirements, procurement rules and the willingness of suppliers to serve a low-volume market.

A practical loss-of-exclusivity timeline is:

Period Commercial activity
24-36 months before expiry Patent and regulatory review; assess Italian and EU launch plans
12-24 months before expiry Prepare local generic or biosimilar access; identify importer
6-12 months before expiry Confirm pricing, reimbursement and procurement requirements
At expiry Submit or activate local authorization and supply arrangements
First 12 months after expiry Compete on availability, price and tender participation
Later stage Consolidate supply through regional wholesalers and pharmacy channels

Generic entry risk is highest for small-molecule products with expired core patents, multiple EU-approved suppliers and low technical complexity. Risk is lower for sterile injectables, complex formulations, biologics, controlled products and medicines with unstable supply economics.

What is the Orange Book status of San Marino medicines?

San Marino has no FDA Orange Book. The relevant question is whether the product has an enforceable patent or exclusivity right in San Marino and whether the product can legally be imported and supplied.

For a generic launch, companies should conduct a jurisdiction-specific review of:

  • Active patents extending to San Marino.
  • European patent validation.
  • Supplementary protection certificates, if applicable.
  • Formulation and device patents.
  • Manufacturing patents.
  • Regulatory data protection.
  • Market authorization and reimbursement barriers.
  • Distribution and parallel-import restrictions.

Are Paragraph IV challenges available in San Marino?

The U.S. Paragraph IV certification system does not apply in San Marino. San Marino also should not be presumed to offer the same statutory patent-certification mechanism used in the United States or the same centralized litigation dynamics found in larger European markets.

A generic company challenging a patent would typically rely on applicable national patent law and civil litigation procedures. The principal legal questions are validity, infringement, territorial effect and available remedies. A generic may also choose to enter after expiry without challenging the patent, subject to authorization and supply requirements.

The small market may reduce the economic rationale for standalone litigation. Companies are more likely to assess San Marino as part of a wider European launch and use Italian or regional litigation strategy where the commercial exposure is materially larger.

How do pricing and reimbursement work?

San Marino’s reimbursement and procurement system is closely tied to its public health infrastructure. The ISS is likely to have a central role in determining which medicines are supplied or reimbursed through public channels.

Market access may involve:

  • Inclusion in public formularies.
  • Hospital or institutional procurement.
  • Pharmacy reimbursement.
  • Tender or negotiated purchasing.
  • Reference to Italian prices.
  • Therapeutic substitution or generic preference.
  • Budget-impact review for high-cost medicines.

A low list price is not sufficient for access. The supplier also needs reliable local distribution, appropriate packaging, Italian-language information, batch traceability and continuity of supply.

High-cost therapies may require a budget-impact submission or negotiated reimbursement arrangement. For generics, the decisive factors are often net price, availability, tender eligibility and substitution policy.

What manufacturing and supply-chain barriers exist?

San Marino has limited domestic pharmaceutical manufacturing capacity. Manufacturers generally access the market through importation from Italy or another qualified European supplier.

Key barriers include:

  • Dependence on external wholesalers.
  • Small minimum-order volumes.
  • Limited local inventory.
  • Cold-chain management.
  • Product shortages in Italy.
  • Batch-release and traceability requirements.
  • Italian-language packaging.
  • Recall coordination.
  • Controlled-substance handling.
  • Distributor margin pressure.

A manufacturer should designate a reliable importer with documented GDP capability and the ability to manage customs, storage, recalls, returns and pharmacovigilance communications.

For biologics, vaccines and temperature-sensitive products, the supply agreement should define temperature excursion handling, data logging, replacement obligations and responsibility for product complaints.

Which companies are likely to challenge branded products?

San Marino does not have a large domestic generic industry. Competition is more likely to come from multinational and European generic suppliers operating through Italian distributors. Relevant competitor groups include:

  • Teva.
  • Sandoz.
  • Viatris.
  • Zentiva.
  • EG Stada.
  • Krka.
  • Accord Healthcare.
  • Fresenius Kabi.
  • Hikma.
  • Specialist biosimilar companies.

The actual competitive set varies by molecule, authorization holder, tender participation and wholesaler relationships. Local pharmacy purchasing may favor suppliers that can provide dependable delivery even when their nominal price is not the lowest.

How does San Marino compare with Italy and the European Union?

Issue San Marino Italy European Union
EU member state No Yes Yes
Centralized EU authorization automatically effective No Yes, subject to EU rules Yes in applicable scope
National authorization Required or otherwise locally recognized AIFA or EU route National or centralized routes
Market size Very small Large Very large
Procurement concentration High Mixed Mixed
Generic competition Import-driven Strong Strong
Patent litigation economics Limited Material Material
Regulatory complexity Lower volume but cross-border Highly structured Harmonized but administratively complex
Commercial model Regional add-on market Standalone national market Multi-country platform

San Marino is easier to cover operationally than Italy, but it is not simply an Italian province from a legal perspective. The most efficient model is usually a San Marino-specific compliance workstream attached to an Italian commercial and supply platform.

What litigation and settlement risks affect the market?

Publicly visible pharmaceutical patent litigation in San Marino is limited compared with Italy, Germany, France or the United Kingdom. The principal risks are likely to arise from:

  • Patent enforcement against imported generics.
  • Distribution or parallel-import disputes.
  • Trademark conflicts.
  • Product liability.
  • Supply interruptions.
  • Tender challenges.
  • Reimbursement decisions.
  • Counterfeit or unauthorized-import allegations.

Settlement agreements involving San Marino may be embedded in broader European agreements. A company should review territorial clauses carefully. A settlement that permits launch in selected EU countries may not automatically address San Marino, and a restriction covering European territories may include San Marino depending on the drafting.

What is the commercial outlook for branded and generic drugs?

The commercial outlook is stable but narrow. San Marino is best viewed as a low-volume, high-compliance extension market.

Segment Outlook Main success factor
Conventional generics Positive Competitive price and reliable supply
Branded generics Moderate Local distributor and pharmacy access
Specialty medicines Positive in selected products Reimbursement and clinical need
Biosimilars Selective Institutional procurement and physician adoption
Vaccines Selective Public-health purchasing and cold chain
Orphan drugs High value, low volume Patient identification and funding
OTC medicines Moderate Pharmacy placement and consumer demand
Complex injectables Selective GDP, cold chain and hospital supply

Revenue exposure for a global manufacturer is unlikely to be material on a consolidated basis. The market can still affect regional launch sequencing, supply continuity, tender reference pricing and regulatory precedent.

Key Takeaways

  • San Marino is a micro-market supplied mainly through Italy and European distributors.
  • EU or Italian authorization does not automatically eliminate San Marino-specific market-access steps.
  • ISS and public-sector procurement are central to reimbursement and institutional sales.
  • Generic opportunity is strongest in established chronic-care medicines with simple logistics.
  • Specialty medicines and biosimilars can generate value despite low patient numbers.
  • San Marino has no U.S.-style Orange Book or Paragraph IV system.
  • Patent analysis must confirm European patent validation and territorial enforceability.
  • Litigation is likely to be limited by market size, but importation, tender and supply disputes remain relevant.
  • The best commercial model is an Italy-led regional platform with local regulatory and distribution controls.

FAQs

Can an Italian marketing authorization be used to sell medicines in San Marino?

Not automatically. The Italian authorization can support the San Marino regulatory file, but local recognition, notification, importation and reimbursement requirements may still apply.

Does San Marino accept centralized EU marketing authorizations?

A centralized EU authorization is an important regulatory foundation, but San Marino is not an EU member state. Local authorities may require a separate national administrative step before commercial supply.

Is San Marino attractive for a first generic launch?

Usually not as a standalone first-launch market. It is more efficient as part of a broader Italy or EU generic launch supported by an established wholesaler.

Are biosimilars reimbursed in San Marino?

Biosimilar access depends on ISS reimbursement, procurement decisions, applicable substitution policy and institutional purchasing. EU approval alone does not guarantee reimbursement.

Can a patent owner block parallel imports into San Marino?

Potentially, depending on the patent’s territorial effect, exhaustion rules, product authorization and importation structure. A product-by-product legal analysis is required.

References

European Patent Office. (2024). Member states of the European Patent Organisation. https://www.epo.org

International Monetary Fund. (2024). San Marino: Country data and economic indicators. https://www.imf.org

U.S. Department of State. (2024). 2024 investment climate statements: San Marino. https://www.state.gov

World Bank. (2024). San Marino data. https://data.worldbank.org/country/san-marino

World Health Organization. (2023). San Marino: Health system and pharmaceutical policy information. https://www.who.int/countries/smr/

More… ↓

⤷  Start Trial

DrugPatentWatch cited by CNN, NEJM, Nature Journals, and more …

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. We do not provide individual investment advice. This service is not registered with any financial regulatory agency. The information we publish is educational only and based on our opinions plus our models. By using DrugPatentWatch you acknowledge that we do not provide personalized recommendations or advice. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.